[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yongquan Shi\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":180},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,73,95,117,142,163],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100634931","phase-4-comparative-effectiveness-of-upadacitinib-vs-corticosteroids-as-first-line-therapy-for-acute-severe-ulcerative-colitisupfront-100634931",false,"NCT07546097","Comparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis（UPFRONT）","Comparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis: Multicenter, Open-label, Non-inferiority, Randomized Controlled Study","Inclusion Criteria:\n\n* Patients diagnosed with ASUC\n* Aged 18 years or older.\n* No gender restriction.\n\nExclusion Criteria:\n\n* Presence of contraindications, allergy, or intolerance to upadacitinib or glucocorticoids.\n* Patients requiring immediate colectomy; diagnosis of Crohn's disease; confirmed intestinal infection; hemodynamic instability; clinically significant cytomegalovirus infection; current malignancy.\n* Presence of severe underlying systemic diseases involving the heart, lungs, liver, kidneys, hematologic system, or other organ systems.\n* Pregnant or breastfeeding women.\n* Unwilling to participate in the clinical study.","ALL","18 Years","85 Years",{"count":20,"type":21},46,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to learn comparative effectiveness and safety of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis. The main questions it aims to answer are:\n\n1. Whether upadacitinib can effectively induce remission in acute severe ulcerative colitis with an efficacy non-inferior to that of corticosteroids.\n2. What adverse reactions may occur with upadacitinib in the treatment of acute severe ulcerative colitis?\n\nResearchers will compare upadacitinib with corticosteroids to evaluate the efficacy of upadacitinib in the treatment of acute severe ulcerative colitis.Participants will:\n\n1. Upadacitinib group: Upadacitinib extended-release tablets 45 mg once daily for 8 weeks, then adjusted to 30 mg once daily.\n2. Corticosteroid group: Methylprednisolone for injection 60 mg\u002Fday. If clinical response is achieved, switch to oral prednisone acetate tablets after 5 days (calculated at 0.75 mg\u002Fkg\u002Fday), followed by a weekly prednisone taper of 5 mg. When the dose is reduced to 20 mg, taper by 2.5 mg weekly until discontinued, with mesalazine 4 g\u002Fday as maintenance therapy.\n3. Take drug Upadacitinib or Corticosteroid every day for 3 months\n4. Visit the clinic once every 2 weeks for checkups and tests\n5. Record the patient's bowel movements and the presence of symptoms such as abdominal pain, while performing colonoscopy, ultrasound examination, and blood tests at the specified time points.",[27],"Acute Severe Ulcerative Colitis",[29,30,31,32,33],"acute severe ulcerative colitis","Upadacitinib","Corticosteroids","First-Line Therapy","Randomized Controlled Trial","RECRUITING","2026-06-11",{"date":37,"type":38},"2026-06-15","ACTUAL",{"date":40,"type":38},"2026-03-23",{"date":42,"type":21},"2027-06-30",{"name":44,"class":45},"Yongquan Shi","OTHER",4,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100634666","association-between-microplastic-exposure-and-the-pathological-progression-of-gastric-carcinogenesis-100634666","NCT07542652","Association Between Microplastic Exposure and the Pathological Progression of Gastric Carcinogenesis","Association of Microplastic Exposure With Pathological Stages of Gastric Mucosal Carcinogenesis: A Cross-Sectional Study","Inclusion Criteria:\n\n* Aged between 18 and 75 years old, gender is not restricted\n* Having a clear diagnosis result within the recent three months and being diagnosed with chronic non - atrophic gastritis, precancerous lesions of gastric cancer, or gastric cancer for the first time\n* Have clear Helicobacter pylori (Hp) test results\n* Be in normal mental state and able to independently complete the questionnaire survey\n\nExclusion Criteria:\n\n* Patients with a history of malignant tumors in other parts\n* Patients who have previously undergone upper gastrointestinal surgery, chemotherapy, or radiotherapy\n* Patients with severe diseases of major organs such as the heart, lungs liver, and kidneys\n* Patients who are currently receiving psychological intervention or taking psychiatric drugs\n* Pregnant or lactating women\n* Patients with severe missing clinical data or questionnaire information\n* Refusing to sign the informed consent form","75 Years",{"count":56,"type":21},450,"OBSERVATIONAL","The objective of this clinical trial is to explore the correlation between the level of microplastic exposure and the risk of gastric mucosal carcinogenesis, and to evaluate the strength of its effect as an independent risk factor. The main questions it aims to answer include: Does the level of microplastic exposure increase the risk of gastric mucosal carcinogenesis? Can the correlation between the level of microplastic exposure and gastric mucosal carcinogenesis, as well as the sources of high - risk microplastic exposure, be explored through a questionnaire on external microplastic exposure? Researchers will complete a design structured questionnaire and ask participants to fill it out carefully and truthfully to determine whether the level of microplastic exposure increases the risk of gastric mucosal carcinogenesis.",[60,61,62,63],"Gastric Carcinoma","Gastritis Chronic","Intestinal Metaplasia","Gastric Precancerous Lesions","2026-04-25",{"date":66,"type":38},"2026-04-30",{"date":68,"type":38},"2026-03-31",{"date":70,"type":21},"2026-12-31",{"name":44,"class":45},1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":72},"100563516","phase-2-efficacy-and-safety-of-thalidomide-combined-with-glutamine-in-the-treatment-of-radiation-intestinal-injury-100563516","NCT06617182","Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury.","Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury: a Single-center, Open-label, Randomized Controlled Study","Inclusion Criteria:\n\n* Age 18-80 years old, gender is not limited;\n* Patients with hematochezia symptoms of chronic radiation intestinal injury: Due to the lack of diagnostic gold standard for radiation intestinal injury, a comprehensive analysis of clinical, endoscopic, imaging and histopathological findings was mainly performed to make the diagnosis of radiation intestinal injury on the basis of excluding infectious and other non-infectious intestinal injuries. Exposure to radioactive sources is a necessary factor in the diagnosis of radiation intestinal injury, and tumor activity or recurrence should be excluded.\n* The proportion of dominant defecation bleeding in total defecation times in the week before treatment is not less than 20%;\n* ECOG score: 0-2.\n\nExclusion Criteria:\n\n* Patients with hemodynamic instability;\n* Patients with obvious liver and kidney function injury: bilirubin, aminotransferase (ALT, AST) exceeded the upper limit of normal by 2 times; eGFR\\\u003C60ml\u002Fmin or dialysis patients;\n* Patients allergic to thalidomide or glutamine;\n* Patients whose primary disease was gastrointestinal malignancy;\n* Patients currently suffering from serious or uncontrolled underlying diseases of the blood, digestive tract, metabolism, endocrine, lung, heart, nervous system, mental system, etc.;\n* Female patients during pregnancy and breastfeeding (including patients with reproductive needs);\n* Patients infected with HIV;\n* Patients who cannot cooperate with regular follow-up and review of laboratory indicators;\n* any other circumstances which, in the opinion of the investigator, would render the subject unfit for study inclusion.","80 Years",{"count":82,"type":21},150,[84],"PHASE2","At present, there is still a lack of standard and effective treatment strategies and procedures for radiation intestinal injury. Studies have shown that thalidomide can effectively treat refractory gastrointestinal bleeding caused by vascular malformation. Therefore, The investigators designed a single-center, open-label, randomized controlled study to evaluate the efficacy and safety of thalidomide combined with glutamine in the treatment of radiation intestinal injury.",[87],"Radiation Enteritis",{"date":89,"type":38},"2026-03-27",{"date":91,"type":38},"2024-09-30",{"date":93,"type":21},"2028-11-01",{"name":44,"class":45},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},"100563022","phase-4-efficacy-and-safety-of-ursodeoxycholic-acid-in-reversing-gastric-intestinal-metaplasia-100563022","NCT06610760","Efficacy and Safety of Ursodeoxycholic Acid in Reversing Gastric Intestinal Metaplasia","Efficacy and Safety of Ursodeoxycholic Acid in Reversing Gastric Intestinal Metaplasia: A Multicenter, Randomized, Placebo-Controlled Trial","Inclusion Criteria:\n\n* patients aged from 18 to 75 years old.\n* patients with OLGIM stage Ⅱ-Ⅳ diagnosed by upper gastrointestinal endoscopy and histopathological examination within the last 3 months.\n* patients without Helicobacter pylori infection, including patients who had successful Helicobacter pylori eradication before enrollment.\n\nExclusion Criteria:\n\n* a history of regular use (defined as at least once per week) of non-steroidal anti-inflammatory drugs (NSAIDs) and\u002For statins.\n* a history of stomach surgery (including endoscopic submucosal dissection and endoscopic mucosal resection) or previously diagnosed malignant tumor.\n* a history of heart failure, renal failure, liver cirrhosis or chronic hepatic failure; patients with contraindications or allergies to the drugs in this study.\n* breastfeeding or pregnancy.\n* a history of substance abuse or alcohol abuse within the past one year.\n* patients with severe mental illness.\n* refusal to undergo drug treatment.\n* refusal to sign informed consent.",{"count":103,"type":21},196,[24],"The goal of this clinical trial is to investigate the efficacy of ursodeoxycholic acid in treating gastric intestinal metaplasia in Helicobacter pylori-negative adults. It will also learn about the safety of ursodeoxycholic acid. The main questions it aims to answer are:\n\nDoes ursodeoxycholic acid promote the regression of IM in individuals without Helicobacter pylori infection? What medical problems do participants experience when taking ursodeoxycholic acid? Researchers will compare ursodeoxycholic acid to a placebo (a look-alike substance that contains no drug) to see if ursodeoxycholic acid is effective in treating gastric intestinal metaplasia.\n\nParticipants will:\n\nTake ursodeoxycholic acid or a placebo every day for 6 months. Visit the clinic once every 4 weeks for checkups and tests.",[107],"Gastric Intestinal Metaplasia","2025-12-04",{"date":110,"type":38},"2025-12-05",{"date":112,"type":38},"2024-11-12",{"date":114,"type":21},"2026-10-31",{"name":44,"class":45},6,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":72},"100603657","phase-4-saccharomyces-boulardii-combined-with-bismuth-quadruple-therapy-for-helicobacter-pylori-rescue-treatment-100603657","NCT07139366","Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment","Efficacy and Safety of Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment: A Prospective, Multicenter, Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18\\~75, both gender.\n* Patients who had failed H.pylori eradication therapies .\n* Women are eligible if they are not pregnant or nursing, and if they are of childbearing potential they are required to use medically acceptable contraception for the duration of the study and 30 days thereafter.\n\nExclusion Criteria:\n\n* Patients who have previously used tetracycline and furazolidone antibiotics to eradicate infection with H. pylori.\n* Contraindications to study drugs.\n* Substantial organ impairment, severe or unstable cardiopulmonary or endocrine disease.\n* Constant use of anti-ulcer drugs ( including taking proton-pump.inhibitors(PPI) within 2 weeks before the \\[13C\\] urea breath test), antibiotics or bismuth complexes (more than 3 times \u002F1 month before screening).\n* Pregnant or lactating women.\n* Underwent upper gastrointestinal Surgery.\n* Dysphagia.\n* Evidence of bleeding or iron efficiency anemia.\n* A history of malignancy.\n* Drug or alcohol abuse history in the past 1 year.\n* Systemic use of corticosteroids, non steroidal anti-inflammatory drugs, anticoagulants, platelet aggregation inhibitors (except the use of aspirin for less than 100 mg\u002Fd).\n* Mental disorder.\n* Enrolled in other clinical trials in the past 3 months.\n* Refuse to sign informed consent.",{"count":125,"type":21},1248,[24],"This study aims at evaluating efficacy and safety of Saccharomyces boulardii combined with bismuth-containing quadruple Therapy versus bismuth-containing quadruple Therapy(bismuth#esomeprazole#tetracycline and furazolidone) in H. pylori rescue therapy. It is hypothesized that Saccharomyces boulardii combined with bismuth-containing quadruple Therapy is superior to bismuth-containing quadruple Therapy. Patients with confirmed failure of H. pylori eradication will be randomized to one of the treatments described above. At week 6 follow-up visits, a urea breath test#rapid urease test or helicobacter pylori stool antigen test will be performed to confirm eradication.",[129,130,131,132,133],"Gastritis","Dyspepsia","Helicobacter Pylori Infection","Gastric Cancer","Peptic Ulcer","2025-11-30",{"date":136,"type":38},"2025-12-02",{"date":138,"type":38},"2025-10-28",{"date":140,"type":21},"2026-09",{"name":44,"class":45},{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":72},"100598216","phase-4-efficacy-comparison-of-vonoprazan-combined-with-different-antibiotics-in-dual-therapy-for-helicobacter-pylori-eradication-a-prospective-randomized-controlled-clinical-trial-100598216","NCT07068607","Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. Aged 18 - 70 years, regardless of gender;\n2. Patients with definite Hp infection (positive result in any one of the 13C\u002F14C urea breath test, rapid urease test, and fecal Hp antigen test) who have never received Helicobacter pylori eradication treatment;\n3. For women of child - bearing age, it is required to use medically acceptable contraceptive methods during the trial period and within 30 days after the end of the trial.\n\nExclusion Criteria:\n\n1. Patients who have been definitely diagnosed with Hp infection and have received antibiotic eradication treatment;\n2. Patients with contraindications to the study drug or who are allergic to the study drug;\n3. Patients with severe organ damage and complications (such as liver cirrhosis, uremia, etc.), severe or unstable cardiopulmonary or endocrine diseases;\n4. Patients who have been continuously using anti - ulcer drugs (including taking PPI within 2 weeks before the Hp infection test), antibiotics or bismuth complexes (more than 3 times a week within 1 month before screening);\n5. Pregnant and lactating women;\n6. Patients who have undergone upper gastrointestinal surgery;\n7. Patients with moderate or severe atypical hyperplasia or high - grade intraepithelial neoplasia;\n8. Patients with symptoms of dysphagia;\n9. Patients with evidence of bleeding or iron - deficiency anemia;\n10. Patients with a history of malignant tumors;\n11. Patients with a history of drug or alcohol abuse within the past 1 year;\n12. Patients who are using systemic glucocorticoids, non - steroidal anti - inflammatory drugs, anticoagulants, platelet aggregation inhibitors (except for using aspirin ≤ 100 mg\u002Fd);\n13. Patients with mental disorders;\n14. Patients who have participated in other clinical trials within the past 3 months;\n15. Patients who refuse to sign the informed consent form.","70 Years",{"count":150,"type":21},400,[24],"This study aims to evaluate the efficacy of vonoprazan combined with different antibiotics in dual therapy for Helicobacter pylori eradication treatment. Newly infected patients were randomly assigned to four groups: amoxicillin dual therapy, tetracycline dual therapy, minocycline dual therapy, and bismuth quadruple therapy. At the follow - up visit in the 6th week, urea breath test, rapid urease test, or Helicobacter pylori fecal antigen test will be conducted to confirm eradication.",[154],"Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer","2025-08-12",{"date":157,"type":38},"2025-08-14",{"date":159,"type":38},"2025-04-01",{"date":161,"type":21},"2025-11-01",{"name":44,"class":45},{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":170,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":179,"locationsCount":72},"100562984","phase-4-efficacy-and-safety-of-weifuchun-tablet-in-reversing-gastric-intestinal-metaplasia-100562984","NCT06610266","Efficacy and Safety of Weifuchun Tablet in Reversing Gastric Intestinal Metaplasia","Efficacy and Safety of Weifuchun Tablet in Reversing Gastric Intestinal Metaplasia: A Multi-center, Open-label, Randomized Controlled Trial",{"count":150,"type":21},[24],"The goal of this clinical trial is to investigate the efficacy and safety of Weifuchun tablet in treating gastric intestinal metaplasia in Helicobacter pylori-negative adults. The main questions it aims to answer are: Does Weifuchun tablet promote the regression of gastric intestinal metaplasia in individuals without Helicobacter pylori infection? What medical problems do participants experience when taking Weifuchun tablet? Researchers will compare the effectiveness of Weifuchun tablet in treating gastric intestinal metaplasia with that of folic acid, as suggested by the Chinese consensus on management of gastric epithelial precancerous conditions and lesions (2020). Participants will: Take Weifuchun tablets or folic acid every day for 6 months. Visit the clinic once every 4 weeks for checkups and tests.",[107],"2025-07-01",{"date":175,"type":38},"2025-07-02",{"date":177,"type":38},"2025-02-28",{"date":114,"type":21},{"name":44,"class":45},""]